What Type of Patient Can Benefit From PRRT ?
For the past two decades, radiolabeled somatostatin analogs have been employed to treat well-differentiated neuroendocrine tumors (NETs) that express the somatostatin receptor (SSTR) type 2. The most often used peptides are 177Lutetium (177Lu)-DOTATATE and 90Yttrium (90Y)-DOTATOC, which release a beta…